Panelists Announced for Second Annual Regen Med and Advanced Therapies Investor Day; March 26 in New York - Seite 2
David Smith, M.B.A., Head of Therapeutic Cell Solutions, Lonza
2014 Presenting Companies:
Aastrom Biosciences, ACT, Athersys, Biomatrica, BioTime, bluebird bio, BrainStorm Cell Therapeutics, Capricor, Cardio3 Biosciences, Cellular
Dynamics International, Cesca Therapeutics, Cytori Therapeutics, Fate Therapeutics, Fibrocell Science, Harvard Apparatus Regenerative Technology, ISTO Technologies, Juventas Therapeutics, MEDIPOST
America, MiMedx Group, NeoStem, Organovo, Osiris Therapeutics, Oxford BioMedica, Pluristem Therapeutics, Prima BioMed, Promethera Biosciences, Regeneus, ReNeuron, Sangamo BioSciences, StemCells,
Inc. and TiGenix.
This one-day meeting is the only investment conference designed specifically to provide institutional investors and life science analysts with insight into key value drivers at the leading small- and mid- cap regenerative medicine and advanced therapy companies. The event will be held March 26, 2014 beginning at 8:00 am at the Metropolitan Club, New York, NY.
The meeting is sponsored by BioLife Solutions, Celgene Corporation, Lonza, NeoStem, Progenitor Cell Therapy (PCT) and Westwicke Partners and in partnership with ProActive Capital and The Life Science Report. For more information including the program's agenda, visit the event's website at http://arminvestorday.com/. Credentialed investors, life science strategic partners and members of the media should contact Laura Parsons at lparsons@alliancerm.org if interested in attending.
About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based multi-stakeholder advocacy organization that promotes
legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field
and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the
formation of ARM in 2009, there was no advocacy organization operating in Washington, DC to specifically represent the interests of the companies, research institutions, investors and patient
groups that comprise the entire regenerative medicine community. Today ARM has more than 150 members and is the leading global advocacy organization in this field. To learn more about ARM or to
become a member, visit www.alliancerm.org.
Lesen Sie auch
Media Contact:
Michelle Linn
Linnden Communications
Phone: 508-362-3087